Gene Transfer Technology May Pave Way For HIV Vaccine

Using gene transfer technology, scientists have developed a new approach to overcome the biggest hurdle in the development of an effective HIV vaccine.

Scientists may yet be able to overcome their biggest hurdle in the development of an effective HIV vaccine by using gene transfer technology.

The researchers used gene transfer technology, which produces molecules that block infection, to successfully protect monkeys from infection by a virus closely related to HIV-the simian immunodeficiency virus, or SIV-that causes AIDS in rhesus monkeys.

Researchers Find the Reason for Failure of HIV Vaccine
Researchers says that the reason why the STEP trial of an experimental vaccine against AIDS failed could be partially because it made some people’s immune cells more vulnerable to HIV infection.

"We used a leapfrog strategy, bypassing the natural immune system response that was the target of all previous HIV and SIV vaccine candidates," Nature magazine quoted study leader Dr. Philip R. Johnson, chief scientific officer at The Children's Hospital of Philadelphia, as saying.

Johnson developed the novel approach over a ten-year period, but warned that many hurdles still remain before the technique could be translated into an HIV vaccine for humans.

Most attempts at developing an HIV vaccine have used substances aimed at stimulating the body's immune system to produce antibodies or killer cells that would eliminate the virus before or after it infected cells in the body. But, the approach has not been proved fruitful until now.

HIV Vaccine Fails to Give Promising Results
A clinical trial testing the effectiveness of what was believed to be a promising new HIV vaccine has resulted in failure.

However, the approach used in the current study was divided into two phases-in the first phase, researchers created antibody-like proteins (called immunoadhesins) that were specifically designed to bind to SIV and block it from infecting cells.

After it was proven to work against SIV in the laboratory, DNA representing SIV-specific immunoadhesins was engineered into a carrier virus designed to deliver the DNA to monkeys.

Experimental HIV Vaccine Trials at Merck and Co. Caused More Infections
Trials of a once-promising experimental HIV vaccine were cut short in 2007 because the drug may have increased the likelihood of HIV infection rather than preventing it, according to a new study.

The researchers chose adeno-associated virus (AAV) as the carrier virus because it is a very effective way to insert DNA into the cells of a monkey or human.

In the second part of the study, the team injected AAV carriers into the muscles of monkeys, where the imported DNA produced immunoadhesins that entered the blood circulation.

Africa�s HIV Volunteers Warned About Possible Increased Risk of HIV
HIV/AIDS researchers in South Africa on Tuesday began warning 801 volunteers who participated in a trial of Merck's experimental HIV vaccine about a possible increased risk of HIV

After a month of administrating the AAV carriers, the immunized monkeys were injected with live, AIDS-causing SIV.

It was found that the majority of the immunized monkeys were completely protected from SIV infection, and all were protected from AIDS, unlike a group of unimmunized monkeys, who were infected by SIV, and two-thirds died of AIDS complications.

"To ultimately succeed, more and better molecules that work against HIV, including human monoclonal antibodies, will be needed," said Johnson and his co-authors.

The study has appeared in the online version of Nature Medicine.

Source-ANI
TAN